Primary central nervous system lymphoma: Immunohistochemical profile and prognostic significance

Neuropathology

Volumn 30, Issue 3, 2010, Pages 232-240

  Raoux, Delphine ^a   Duband, Sébastien ^a   Forest, Fabien ^a   Trombert, Béatrice ^a   Chambonnière, Marie Laure ^a   Dumollard, Jean Marc ^a   Khaddage, Abir ^a   Gentil Perret, Anne ^a   Péoc'h, Michel ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Diffuse large B cell lymphoma; Immunohistochemical; Primary central nervous system lymphoma; Prognostic subgroups G1 and G2; Prognostic subgroups GCB and non GCB

Indexed keywords

BIOLOGICAL MARKER; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 2; PROTEIN BCL 6;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CENTRAL NERVOUS SYSTEM NEOPLASMS; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77952898448     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2009.01074.x     Document Type: Article

References (48)

1. Bailey P. Intracranial sarcomatous tumors of leptomeningeal origin. Arch Surg 1929 18 : 1359 1402.
2. Henry JM, Heffner RR, Dillard SH, Earle KM, Davis LD. Primary malignant lymphomas of the central nervous system. Cancer 1974 34 : 1293 1302.
3. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006 24 : 1281 1288.
4. Lister A, Abrey LE, Sandlund JT. Central nervous system lymphoma. Haematol Am Soc Haematol Educ Program 2002 283 296.
5. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 2000 403 : 503 511.
6. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002 346 : 1937 1947.
7. Huang JZ, Sanger WG, Greiner TC et al. The t(14; 18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002 99 : 2285 2290.
8. Iqbal J, Sanger WG, Horsman DE et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004 165 : 159 166.
9. Bea S, Zettl A, Wright G et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression based survival prediction. Blood 2005 106 : 3183 3190.
10. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 : 275 282.
11. Berglund M, Thunberg U, Amini RM et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact of prognosis. Modern Pathol 2005 18 : 1113 1120.
12. Chang CC, McClintock S, Cleveland RP et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004 28 : 464 470.
13. Camilleri-Broët S, Crinière E, Broët P et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006 107 : 190 196.
14. Lin CH, Kuo KT, Chuang SS et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 2006 12 : 1152 1156.
15. Bhagavathi S, Sharathkumar A, Hunter S et al. Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas. Clin Neuropathol 2008 27 : 13 20.
16. Muris JJ, Meijer CJ, Vos W et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006 208 : 714 723.
17. Larocca LM, Capello D, Rinelli A et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B-cells. Blood 1998 92 : 1011 1019.
18. Thompsett AR, Ellison DW, Stevenson FK, Zhu DV. H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center-B cells with ongoing mutational activity. Blood 1999 94 : 1738 1746.
19. Rubenstein JL, Fridlyand J, Shen A et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006 107 : 3716 3723.
20. Tun HW, Personett D, Baskerville KA et al. Pathway analysis of primary central nervous system lymphoma. Blood 2008 111 : 3200 3210.
21. Barrans SL, Carter I, Owen RG et al. Germinal centre phenotype and Bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B cell lymphoma. Blood 2002 99 : 1136 1143.
22. Hermine O, Haioun C, Lepage E et al. Prognostic significance of Bcl-2 protein expression in aggressive non-hodgkin's lymphoma. Groupe d'Etude des lymphomes de l'Adulte (GELA). Blood 1996 87 : 265 272.
23. Jaffe ES, Lee Harris N, Stein H, Vardiman JW. Pathology and genetics: tumors of hematopoietic and lymphoid tissues. In : Kleihues P, Sobin LH, eds. World Health Organization Classification of Tumors.
24. Eby NL, Grufferman S, Flannelly CM, Scold SC Jr., Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the US. Cancer 1988 62 : 2461 2465.
25. Kadan-Lottick NS, Skluzacek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002 95 : 193 202.
26. Peoc'h M, Le Marc'hadour F, Pasquier B. Primary central malignant lymphomas. Am J Surg Pathol 1995 19 : 1217 1218.
27. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993 119 : 1093 1104.
28. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 1999 43 : 199 201.
29. Jahnke K, Korfel A, O'Neill BP et al. International study on Low-grade Primary Central Nervous System Lymphoma. Ann Neurol 2006 59 : 755 762. (Pubitemid 43673153)
30. Bataille B, Delwail V, Menet E et al. Primary intracerebral malignant lymphoma: a report of 248 cases. J Neurosurg 2000 92 : 261 266.
31. Balmaceda C, Gaynor JJ, Sun M, Gluck JT, DeAngelis LM. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol 1995 38 : 202 209.
32. DeAngelis LM, Wong E, Rosenblum M, Furneaux H. Epstein-Barr Virus in Acquired Immune Deficiency Syndrome (AIDS) and Non-AIDS Primary Central Nervous System lymphoma. Cancer 1992 70 : 1607 1611.
33. Yu GH, Montone KT, Frias-Hidvegi D, Cajulis RS, Brody BA, Levy RM. Cytomorphology of Primary CNS Lymphoma: review of 23 cases and evidence for the role of EBV. Diagn Cytopathol 1996 14 : 114 120.
34. Camilleri-Broët S, Martin A, Moreau A et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations: Groupe Ouest Est d'Etudes des Leucémies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol 1998 110 : 607 612.
35. Ferreri AJ, Blay JY, Reni M et al. Pronostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003 21 : 266 272.
36. Nakamura M, Shimada K, Ishida E, Konishi N. Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas. Histol Histopathol 2004 19 : 211 219.
37. Paulus W. Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol 1999 43 : 203 208.
38. Braaten KM, Betensky RA, de Leval L et al. BCL-6 expression predicts improved survival in patients with primary nervous central system. Clin Cancer Res 2003 9 : 1063 1069.
39. Eshoa C, Perkins S, Bunyi-Teopengco E et al. Expression of p53 and EBV-LMP1 correlates with survival in primary central nervous system diffuse large B-cell lymphoma. Mod Pathol 2001 14.
40. Llanos M, Alvares-Arguelles H, Aleman R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of ki-67 nuclear proliferative antigen, bcl-2 protein and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol 2001 18 : 15 22.
41. Chang CC, Kampalath B, Schultz C et al. Expression of p53, c-Myc, or Bcl6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med 2003 127 : 208 212.
42. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997 90 : 244 251. (Pubitemid 27276568)
43. Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large Bcell lymphoma. Blood 2003 101 : 78 84.
44. Iqbal J, Neppalli VT, Wright G et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006 24 : 961 968.
45. Miller TB, Grogan TM, Dahlberg S et al. Prognostic significance of the ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group Trial. Blood 1994 83 : 1460 1466.
46. Tominaga K, Yamaguchi Y, Nozawa Y, Abe M, Wakasa H. Proliferation in non-Hodgkin's lymphomas as determinated by immunohistochemical double staining for ki-67. Hematol Oncol 1993 10 : 163 169.
47. Ferreri AJ, Abrey LE, Blay JY et al. Summary statement on primary central nervous system lymphomas from the Eight International Conference on malignant lymphoma, Lugano, Switzerland. J Clin Oncol 2003 21 : 2407 2414.
48. Montesinos-Rongen M, Bruun A, Bentink S et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 2008 22 : 400 405.